Company / Operating Margin
Taysha Gene Therapies, Inc. Operating Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-1130.7%
FY2025
5-year range
-6925.1% / -468.8%
FY2022-FY2025
Trend
-141.2%
vs FY2024
Sector context
#121 of 136
Health Care
What the data says
Taysha Gene Therapies, Inc.'s operating margin of -1130.7% is lower than 89% of companies in the Health Care sector (FY2025). Improved from -6492.7% to -1130.7% over the past 2 years.
Based on SEC 10-K filings.
-1130.7% in FY2025 with a 3-year CAGR of +5794.5%.
Improved from -6492.7% to -1130.7% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +5794.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 136This company -1130.7% Sector average -778.9%
▼
-45.2% below sector average
Key checks
Key Insights
- In FY2025, operating margin decreased 141.2% year-over-year.
- Currently 351.7pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -1130.7% | -141.2% |
| FY2024 | -468.8% | +92.8% |
| FY2023 | -6492.7% | +6.2% |
| FY2022 | -6925.1% | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026